Benzinga
Benzinga
Actualités France
Bourse
Economie
Général
Actualités Américaines
Bourse
Bénéfices
Economie
Marchés prédictifs
Marchés privés
Autres marchés
Recommandations des analystes
Trading
Communiqués de presse
Mondial
Asie
Crypto-monnaies
Actualités cryptos
Altcoins
Bitcoin
Dogecoin
Ethereum
Shiba Inu
NFT
Éducation
Investir en crypto
Investir en bourse
Forex
Benzinga
jeudi, octobre 22
Actualités France
Bourse
Economie
Général
Actualités Américaines
Bourse
Bénéfices
Economie
Marchés prédictifs
Marchés privés
Autres marchés
Recommandations des analystes
Trading
Communiqués de presse
Mondial
Asie
Crypto-monnaies
Actualités cryptos
Altcoins
Bitcoin
Dogecoin
Ethereum
Shiba Inu
NFT
Éducation
Investir en crypto
Investir en bourse
Forex
Vera Therapeutics Inc
VERA
NASDAQ
Liste de surveillance
Get Report
Trade with Public
Get Report
Trade with Public
$30.80
-0.40
-1.28%
Dern. MÀJ: Oct 22, 11:51 AM
$31.12
-0.08
-0.26%
Get Report
Aperçu
Actualités
Prévisions de résultats
Événements
Objectifs de cours
Données financières
Sentiment
Actionnariat
Comparer
Options
Rapport sur les stocks
Privacy Manager
Résultats:
Résultats Q3 2026 dans dans 14 jours à partir de maintenant le jeu. nov. 5th, après la fermeture du marché
Vera Therapeutics Financials
Vera Therapeutics (VERA) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
Vera Therapeutics Q2 EPS $(1.52) Beats $(1.61) Estimate
Vera Therapeutics (NASDAQ:VERA) reported quarterly losses of $(1.52) per share which beat the analyst consensus estimate of $(1.61) by 5.59 percent. This is a 26.67 percent decrease over losses of $(1.20) per share from
Benzinga Newsdesk
PRO
Vera Therapeutics Q1 EPS $(1.69) Misses $(1.34) Estimate
Vera Therapeutics (NASDAQ:VERA) reported quarterly losses of $(1.69) per share which missed the analyst consensus estimate of $(1.34) by 26.12 percent. This is a 108.64 percent decrease over losses of $(0.81) per share
Benzinga Newsdesk
PRO
Vera Therapeutics Q4 EPS $(1.39) Misses $(1.31) Estimate
Vera Therapeutics (NASDAQ:VERA) reported quarterly losses of $(1.39) per share which missed the analyst consensus estimate of $(1.31) by 6.19 percent. This is a 93.06 percent decrease over losses of $(0.72) per share
Benzinga Newsdesk
PRO
Vera Therapeutics Q3 EPS $(1.26) Misses $(1.16) Estimate
Vera Therapeutics (NASDAQ:VERA) reported quarterly losses of $(1.26) per share which missed the analyst consensus estimate of $(1.16) by 8.71 percent. This is a 48.24 percent decrease over losses of $(0.85) per share
Benzinga Newsdesk
PRO
Vera Therapeutics Q2 2025 EPS $(1.20) Misses $(0.83) Estimate, Vera Reported $556.8M In Cash, Cash Equivalents, And Marketable Securities
Vera expects cash position to be sufficient to fund operations through potential approval and us commercial launch of Atacicept anticipated in 2026 and beyond
Benzinga Newsdesk
Crude Oil Gains 2%; ABM Industries Shares Plunge After Q2 Results
Avi Kapoor
